Charlty reglstration number.. 1210455 LMS -RESEARCH LEIOMYOSARCOMA RESEAKH UK TRUSTEES. REPORT AN UNAUDrrED FINANCIAL STATEMENTS FOR THE pER￿D 14 OCTOBER 2024 TO 31 OCTOBER 2025 Godfrey Laws & Co Ltd Lelomyosarcoma Research UK Contents Pag• Reference and Admlnistrative Oetails Trustees. Report Irsdependent Examlner's Report ststernent of Financial Actlvities statement of Flnancial Posltion Ntstes to the Flnanclal sratements The followlng pages do not forrn part of the 5totutory accounts: Detslle# Statement of Flnanclal Activltles io Leiomyosarcoma Research UK Reference and Admlnlstrative Detalls For the Perlod 14 October 2024 to 31 October 2025 Trust••• Mr Colln Grandison (appointed 14/LOI20241 Ms Maisie England Chair lappolnted 14110120241 Ms Julia Casimo lappointed 14110120241 Charlty Numb•r 1210455 Prlnclpil Addr*•• 167 - 169 Great Portland Street London WIW SPF Ind•p*nd•nt Ex•mln•r Howard Ashmore FCA Godfrey Laws & Co Ltd Chartered Accountsnts 65 Knowl Plece Wllbury Way Hitchln Hertlordshire SG4 OTY Page I Leiomyosarcoma Research UK Trustees. Report For the Period 14 October 2024 to 31 October 2025 The trustees present their report and the financial statements for the perlod ended 31 October 202S. ObJ•ctlv•¥ and Actl¥ltl•¥ Alm8 and ObJ•ctlv•• rhe relief of sicknes5 and preservation of health for people sufferlng from Leiomyosarcoma la type of rore cancer that grows In Smooth muscles) In the United Klngdom. in parricular but not exclusively bv., lal Educating the putillc. those suffering from Leiomyosarcoma. and others about Leiomy05arcorna and raising aV4areness of Its prevalence, diagn0515, treatment and latest research. Ibl Promoting and supporting research into Leiomyosarcoma and disseminating the useful results for the publlc benefit. Icl Providin9 support forums, Informatlon. practlcal advlce an¢ Support for people affected by Leiorny05areoma, their famllies and frlends. Sl9nllle•rbt Actl¥ltl•¥ The main activities of the charity within the reportlng period have been the establlshment of the Pathflnder Neh¥ork, whlch will promote research Into Leiomyosarcoma. We have also worked on capaclty and Infrastructure bullding for the charity, estab115hing a website and social media connectyons. Publlc B•n•fSt The Trustees have had regard to the guldance Issued by the C harlty Commlsslon on publlc beneflt. Athl•¥•m•nt• •nd P•rform•nc• M•ln A 40,903 TOTAL ASItT* LEM CURRE￿ UAVLUTiQ% 40.903 NeT ASSE 40.903 FigNDS OF THE CIIAAXYY Unrestrtt*d Funds 40,9QJ TOTAL VUII 40,903 rin b•haW ol ￿ board r Colln Grnnd*o Trustv D•t• The ￿0t5 7 10 9 form of these nnan(1•15tstem•nts. LeioMyosa￿om3 Research UK hk>tes to the Financial Statement$ For the Period 14 October 2024 to 31 October 2025 l. General Inforrnatlon Leiomyosarcoma Research UK Is a Charitable Incorporated or9anisatlon registered with the Charity Commission, reglstered charity number A2L0455. The prlncipal addre55 15 167 - 169 Great Portland Street, London, WIW SPF. 2. Acc?untln9 Pollrl•¥ 2.1. Bas1• of Pr•paratlon of Flnanclal Statements The financial staternents have been prepared In accordance wlth the C haritles SORP IFRS 1021 'Accounting and Reporting by C harities,. Statement of Recommended Practice applicable ro charities preparin9 thelr accounts in accordance with the Flnancial Reporting Standard applicable In the UK and Republic of Ireland IFRS 1021 (effective l January 20191. Financial Reporting Standard 102 'The Flnancial Reporting Standard appllcable in the UK and Republic ol Ireland. and the C hariiies Act 2011. The charity Is è Publlc 8eneflt Enrity as deflned by FRS 102. 2.2. Incomlng R•iourc•s All Incomlng resources are Included In the $tatement of flnancial actl¥ltles when thé charlty Is entlded to, and vlrtually certain to recelve, the incorne and the amount can be quantlfled wlth reasonable accurècy. The rollovling policies are applied to particular categorles of Income.. Voluntary Income Is recelved by vlay of grants, donatlon5 and glft5 and ss Included In full in the Statement of Flnancial Actlvities vlhen receivable. Grants, where entitlement Is not conditional or* the dellvery of a speclflc performance by the charlty, are recognised when the charlty becomes uncondltionally entiUed to the grant. Donated servlces and fatllitles are Included at the value to the charity where this can be quantifled. The value of servlces provided by volunteers has not been Included In theseaccounts. Investment Income Is Includetl when recelvable. Incoming resources from 9rants, where related to performance and speciflc dellverables,ore accounted ror a5 the charity earn5 the right io consideration by its performance. 2.3. R••ourc•• Exp•nd•d Llabllltle5 are reco9nlsed as expendlture as soon as there is a le9al or con5tructlve obllgation commltting the charlty to that expendlture. it Is probable that a transfer of economlc beneflts wlll be requlred In settlement and the amount ol the obllgation can be measured reliably. Expenditure Is accounted for on an accruals basls and has been classilled under headlngs that aggregate all c05t related to the category. Where costs cannot be dlrectly attributed to partlcular headlngs they have been allocated to actlvltles on a basls conslstent with the use of resources. 2.4. Cash •nd Cash Equl¥al•nt• Cash and cash equivalents are basic flnanclal assets and Include cash In hand and deposlts held èt call wlth banks, other short-term highly Ilquld Investynents thar mature In no more than three months from the date of acquisition and are readily convertible to a known amount of casli wlth insignificant risk of change In value, and bank overdrafts. 3. Incom• from Donatlonl and L•gacl•% 31 Octob•r 2025 Unr••trlct•d rund• Donatlons and glfts 43,036 Page 7 Leiomyosarcoma Research UK rtes to the Financial Statements {continued) For the Period 14 October 2024 to 31 October 2025 An•lysls of Exp•ndltur• 31 Ottob•r 2025 A¢tl¥ltl•¥ und•rtak•n dlrectly Support co•t¥ (see note 51 Total Ralslng funtls 1,259 874 2,133 Support C••t• 31 O¢tob•r 2025 R•l•lng lund• Premises expenses General administrabon 96 778 874 6. Ind•p•nd•nt Ex•mln•r'¥ R•mun•r•tlon 31 Octob•r 2025 lThdependent examlnatlon ol the financlal statements 600 A¥•r•9• 14umb•r Ol Empl•y••• Average number of employees during th* p•rlod wa5.. NIL 8. Cr•dltors: Amount• F•lllng Du• Wlthln On• Y••r 31 O¢tob•r 2025 Accruals ond deferred Income 600 Mo¥•m•nt In Fund• A••t14 O¢t•b•r 2024 As•t3A Octob•r 2025 Incorn• exp•ndltur• Vnr*strl¢t¢d lun0• General. General unrestricted Ivnd 43.036 12,1331 40,903 Tot*1 funds 43.036 12, 1331 40,903 Page 8 Leiomyosarcoma Research UK Notes to the Financlal Statements (contlnued) Forthe Period 14 October 2024 to 31 October 2025 10. Tr•n•*ctlons wlth Trust••s None of the trustees received any rernuneration or any other beneflts from an omployment with the